6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine

6,7-Dihydro-5H-Pyrrolo[3,4-B]Pyridine

SCHEMBL103669

c1cnc2c(c1)CNC2

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 US claimed
WO-2024211346-A1 MUTANT PI3K-ALPHA INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2024-10-10 WO claimed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US claimed
US-11434247-B1 Substituted furanopyrimidine compounds as PDE1 inhibitors DART NEUROSCIENCE LLC (US) 2022-09-06 US claimed
EP-3717488-B1 SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS DART NEUROSCIENCE LLC (US) 2021-09-29 EP claimed
US-20210244717-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2021-08-12 US claimed
EP-3717488-A1 SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS Dart NeuroScience, LLC (US) 2020-10-07 EP claimed
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. 2020-09-15 US claimed
CN-111655695-A Substituted furopyrimidines as PDE1 inhibitors 达特神经科学有限公司 2020-09-11 CN claimed
CN-107827816-B Method for synthesizing formamide derivative through graphene oxide catalytic formylation reaction 湘潭大学 2020-01-10 CN claimed
EP-2280964-A1 CHLOROTHIOPHENE-ISOXAZOLES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN Sanofi-Aventis (FR) 2011-02-09 EP claimed
EP-2254881-A1 CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN Sanofi-Aventis (FR) 2010-12-01 EP claimed
CN-101835755-A Novel kinase inhibitors HOFFMANN LA ROCHE 2010-09-15 CN claimed
EP-2205564-A1 NOVEL KINASE INHIBITORS F. Hoffmann-Roche AG (CH) 2010-07-14 EP claimed
WO-2009103440-A1 CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN SANOFI-AVENTIS (FR) 2009-08-27 WO claimed
WO-2009103439-A1 CHLOROTHIOPHENE-ISOXAZOLES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN SANOFI-AVENTIS (FR) 2009-08-27 WO claimed
WO-2009053269-A1 NOVEL KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 WO claimed
US-20090105209-A1 BTK protein kinase inhibitors ROCHE PALO ALTO LLC 2009-04-23 US claimed
US-5312823-A Antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1994-05-17 US claimed
EP-0520277-A2 7-Azaisoindolinyl-quinolone- and naphthyridoncarboxylic acid derivatives BAYER AG (DE) 1992-12-30 EP claimed